Lumaegis

Executive Summary

Lumaegis is a San Diego-based biotech company founded in 2018 that is redefining infection control in healthcare settings. The company is developing innovative solutions for surgical instrument sterilization, with its lead product, the RadBox™ system, designed to provide a safer and more sustainable alternative to traditional sterilization methods. The RadBox™ utilizes a novel small molecule-based approach to achieve rapid and effective sterilization without the need for high heat or toxic chemicals, addressing key pain points in hospital infection control workflows. Lumaegis has positioned itself at the intersection of drug delivery and small molecules, leveraging these technologies to create a platform that could transform how surgical instruments are processed. While the company is still private and at an early stage, its focus on a critical unmet need in healthcare, coupled with a clear product pathway, makes it a compelling investment opportunity. The company is likely to pursue regulatory approvals and strategic partnerships to accelerate commercialization.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round70% success
• H1 2027FDA 510(k) Clearance for RadBox System60% success
• Q2 2027Strategic Partnership with Hospital Network or Sterilization Services Provider50% success